


### **Amendments to the Claims**

This listing of claims will replace all prior versions, and listings of claims in the application.

#### **Listing of Claims:**

1. (previously presented) A method of treating complex regional pain syndrome, which comprises administering to a patient having complex regional pain syndrome about 5 to about 50 mg per day of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione of the formula,



or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

2. (previously presented) The method of claim 1, which further comprises administering to the patient a therapeutically effective amount of at least one second active agent.

3. (original) The method of claim 2, wherein the second active agent is capable of relieving or reducing pain.

4. (original) The method of claim 2, wherein the second active agent is an antidepressant, antihypertensive, anxiolytic, calcium channel blocker, alpha-adrenergic receptor agonist, alpha-adrenergic receptor antagonist, ketamine, anesthetic, muscle relaxant, non-narcotic analgesic, opioid analgesic, anti-inflammatory agent, immunomodulatory agent, immunosuppressive agent, corticosteroid, anticonvulsant, cox-2 inhibitor, hyperbaric oxygen, or a combination thereof.

5. (original) The method of claim 2, wherein the second active agent is salicylic acid acetate, celecoxib, ketamine, gabapentin, carbamazepine, oxcarbazepine, phenytoin, sodium valproate, prednisone, nifedipine, clonidine,


oxycodone, meperidine, morphine sulfate, hydromorphone, fentanyl, acetaminophen, ibuprofen, naproxen sodium, griseofulvin, amitriptyline, imipramine or doxepin.

6 to 8.        canceled.

9.        (previously presented) The method of claim 1, wherein the complex regional pain syndrome is type I or type II.

10 to 22.      canceled.

23.        (previously presented) A method of treating complex regional pain syndrome, which comprises administering to a patient having complex regional pain syndrome, before, during or after surgery, psychological or physical therapy directed at reducing or avoiding a symptom of pain in the patient about 5 to about 50 mg per day of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione of the formula,



or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

24 to 26.      canceled.

27.        (previously presented) The method of claim 1, wherein the compound is 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione.

28.        (previously presented) The method of claim 1, wherein the compound is a pharmaceutically acceptable salt.

29.        (previously presented) The method of claim 1, wherein the compound is a pharmaceutically acceptable solvate.

30.        (previously presented) The method of claim 1, wherein the compound is a pharmaceutically acceptable stereoisomer.

31. (previously presented) The method of claim 30, wherein the stereoisomer is an enantiomerically pure R isomer.

32. (previously presented) The method of claim 30, wherein the stereoisomer is an enantiomerically pure S isomer.

33. (previously presented) The method of claim 1, wherein the compound is administered orally.

34. (previously presented) The method of claim 1, wherein the compound is administered in the form of a tablet or capsule.

35. (new) The method of claim 1, wherein the amount administered is about 5 mg to 25 mg per day.

36. (new) The method of claim 1, wherein the amount administered is about 10 mg per day.

37. (new) The method of claim 1, wherein the amount administered is about 5 mg per day.